Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 03 2019 - 6:16PM
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology
company developing the next generation of cancer immunotherapies to
fight multiple cancer types, today announced that Andrew Allen,
M.D., Ph.D., co-founder, president and chief executive officer,
will present a company overview on Tuesday, Jan. 8, 2019 at 5:30
p.m. PST during the 37th Annual J.P. Morgan Healthcare Conference
in San Francisco. The company will hold a question and answer
session immediately following the presentation.
A live audio webcast will be available within the Investors
& Media section of the Gritstone Oncology website at
https://ir.gritstoneoncology.com/investors. An archived replay will
be accessible for 30 days following the event.
About Gritstone Oncology Gritstone
Oncology (Nasdaq: GRTS), a clinical-stage biotechnology
company, is developing the next generation of cancer
immunotherapies to fight multiple cancer types. Gritstone develops
its products by leveraging two key pillars—first, a proprietary
machine learning-based platform, Gritstone EDGE™, which is designed
to predict, from a routine tumor biopsy, the tumor-specific
neoantigens (TSNA) that are presented on a patient’s tumor cells;
and second, the ability to develop and manufacture potent
immunotherapies utilizing patients’ TSNA to potentially drive the
patient’s immune system to specifically attack and destroy tumors.
The company’s lead product candidate, GRANITE-001, is a
personalized neoantigen-based immunotherapy beginning Phase 1
clinical testing. Gritstone’s second product candidate, SLATE-001,
is a shared neoantigen (“off-the-shelf”) immunotherapy which is
advancing towards the clinic. Novel tumor-specific antigens can
also provide targets for bispecific antibody (BiSAb) therapeutics
for solid tumors, and Gritstone’s BiSAb program is currently in
lead optimization. For more information, please visit
gritstoneoncology.com.
Contacts Media: Dan Budwick 1AB (973) 271-6085
dan@1abmedia.com
Investors: Alexandra Santos Wheelhouse Life Science Advisors
(510) 871-6161 asantos@wheelhouselsa.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024